专利与创新

我们的专利与创新团队是公认的欧洲最优秀的团队之一。我们与世界上最大、技术最丰富和最具创造力的公司均有合作。从初创企业到跨国公司，我们的知识涵盖技术、生命科学、电信、电子和软件行业、化工和汽车等多个领域。

我们深知，让您在本地和国际专利发展中保持领先地位并确保您的发明和创意得到保护非常重要。我们的律师在高价值专利诉讼、专利许可、研发 (R&D) 合作以及解决涉及此类商业关系的合同纠纷方面享有盛誉。事实上，我们的很多律师均拥有内部专业知识和各种技术学位。

由于我们对所有主要国际司法管辖区的专利制度均有深刻了解，因此有能力设计全球专利战略，使您知识产权 (IP) 的跨境价值最大化。

关注领域

生命科学监管咨询专利与专有技术商业协议的起草和谈判专利与专有技术争议解决 Trade secrets

经验

General Catalyst on Series C financing in AI defence pioneer Helsing

Advice to lead investor General Catalyst on all legal aspects of the USD 450 million Series C financing in AI defence pioneer Helsing.

Press release

General Catalyst on Series B financing in AI defence unicorn Helsing

Advice to lead investor General Catalyst on all legal aspects of the USD 223 million Series B financing in AI defence company Helsing. The investment makes Helsing Europe's largest defence AI company.

Press release

OHB on joint venture for clean flying

Advice to space company OHB SE (OHB) on the formation of a joint venture with investment company AFK Enterprise AG (AFK). Furthermore, advice on an agreement to secure a minority stake in Deutsche Aircraft Holdings (DAH), which develops innovative environmentally friendly technologies for aviation.

Press release

Apotex's EUR74 million sale of subsidiaries to Aurobindo

Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.

Colin McCall

Simon Cohen

Tasmina Goraya, PhD

Jason Rawkins

Simon Jupp

Bart Hunnekens

Roos Seesing

Provision of pan-European pharma and patent advice

A leading international healthcare company on provision of European-wide advice across a variety of legal areas including pharmaceutical law and patents.

Dr. Wim Maas

Dr. Wolfgang Rehmann

最新新闻和观点